New Ray Medicine International Holding Limited (stock code: 06108) submitted its Monthly Return for Equity Issuer, covering the period ended 30 November 2025. According to the announcement, the authorized share capital remained at 15,000,000,000 ordinary shares, each with a par value of HKD0.01, totaling HKD150,000,000. There was no change from the previous month.

The company’s issued share capital stayed at 167,184,665 ordinary shares without any treasury shares, reflecting no increase or decrease during the reporting period. Under the share option scheme adopted on 25 October 2013, 12,820,000 share options remained outstanding at the end of November 2025. No new shares were issued, and no funds were raised from exercise of options during the month.

Based on the disclosure, there were no movements in warrants, convertibles, or other share issuance agreements. The company confirmed that all applicable listing and regulatory requirements have been met for the period under review.